Rezolute’s (RZLT) “Outperform” Rating Reiterated at Wedbush

Rezolute (NASDAQ:RZLT)‘s stock had its “outperform” rating reaffirmed by stock analysts at Wedbush in a research report issued to clients and investors on Monday, RTT News reports. They currently have a $112.00 price target on the stock.

Several other brokerages have also recently issued reports on RZLT. Guggenheim began coverage on Rezolute in a research note on Tuesday, August 27th. They issued a “buy” rating and a $11.00 price objective for the company. JMP Securities reissued a “market outperform” rating and issued a $7.00 price objective on shares of Rezolute in a report on Friday, September 20th. Maxim Group upped their price objective on Rezolute from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Tuesday, August 6th. BTIG Research lifted their target price on shares of Rezolute from $13.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, September 10th. Finally, HC Wainwright restated a “buy” rating and set a $14.00 price target on shares of Rezolute in a research report on Friday, September 27th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $24.13.

Rezolute Stock Down 1.1 %

Shares of RZLT traded down $0.06 during mid-day trading on Monday, hitting $5.44. 551,772 shares of the company traded hands, compared to its average volume of 431,836. The company has a market capitalization of $304.26 million, a PE ratio of -4.09 and a beta of 1.18. The business has a 50 day moving average of $4.96 and a 200 day moving average of $4.32. Rezolute has a 1-year low of $0.72 and a 1-year high of $6.10.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings results on Thursday, September 19th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.14). As a group, research analysts expect that Rezolute will post -1.23 EPS for the current fiscal year.

Institutional Trading of Rezolute

A number of institutional investors and hedge funds have recently modified their holdings of RZLT. Jeppson Wealth Management LLC acquired a new stake in Rezolute in the 2nd quarter worth about $45,000. Virtu Financial LLC acquired a new stake in shares of Rezolute in the first quarter worth approximately $37,000. XTX Topco Ltd increased its position in shares of Rezolute by 205.8% during the second quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock worth $145,000 after purchasing an additional 22,660 shares in the last quarter. Cubist Systematic Strategies LLC raised its stake in Rezolute by 366.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 54,237 shares of the company’s stock valued at $233,000 after purchasing an additional 42,597 shares during the last quarter. Finally, Rosalind Advisors Inc. raised its stake in Rezolute by 25.0% in the 2nd quarter. Rosalind Advisors Inc. now owns 250,000 shares of the company’s stock valued at $1,075,000 after purchasing an additional 50,000 shares during the last quarter. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.